Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Notes Payables (2021 - 2025)

Universe Pharmaceuticals' Notes Payables history spans 5 years, with the latest figure at $7.1 billion for Q3 2025.

  • For Q3 2025, Notes Payables rose 22.08% year-over-year to $7.1 billion; the TTM value through Sep 2025 reached $7.1 billion, up 22.08%, while the annual FY2025 figure was $7.1 billion, 22.08% up from the prior year.
  • Notes Payables for Q3 2025 was $7.1 billion at Universe Pharmaceuticals, up from $5.9 billion in the prior quarter.
  • Across five years, Notes Payables topped out at $7.1 billion in Q3 2025 and bottomed at $3.9 million in Q3 2022.
  • The 5-year median for Notes Payables is $5.5 million (2023), against an average of $2.6 billion.
  • The largest annual shift saw Notes Payables decreased 9.19% in 2022 before it soared 106726.27% in 2024.
  • A 5-year view of Notes Payables shows it stood at $4.3 million in 2021, then dropped by 9.19% to $3.9 million in 2022, then soared by 39.28% to $5.5 million in 2023, then skyrocketed by 106726.27% to $5.9 billion in 2024, then increased by 22.08% to $7.1 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Notes Payables are $7.1 billion (Q3 2025), $5.9 billion (Q3 2024), and $5.5 million (Q3 2023).